{"entity":{"id":"idea-fund-academic-sponsor-indemnity-pool","kind":"idea","name":"A public indemnity pool so universities can sponsor first-in-human cancer trials","aka":[],"tldr":"Universities often refuse to be the legal sponsor of a first-in-human trial because they cannot afford the insurance and liability. A shared public insurance pool would remove that block.","summary":"A government- or funder-backed indemnity and insurance pool that covers no-fault compensation and sponsor liability for academic and non-profit sponsored early-phase oncology trials meeting defined quality standards (independent scientific review, GMP product, approved protocol), priced at cost and open to any accredited institution. Sponsor liability and insurance premiums are a frequently cited reason academic legal offices decline to sponsor first-in-human trials of academic products, especially cell and gene therapies, pushing teams to license early on poor terms or to abandon assets. Several countries operate national no-fault schemes for trial injury; extending them to cover sponsor indemnity for academic early-phase trials is a small, cheap change with a large unblocking effect.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)","url":"https://doi.org/10.1038/453840a"}],"tags":[],"related":["idea-fund-global-academic-phase-one-network","idea-fund-public-nonprofit-cro","idea-fund-hospital-exemption-registry"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-translational-valley","b-trial-design"],"keyPapers":["paper-butler-nature"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Where a pool exists, the number of academic-sponsored first-in-human oncology trials rises by at least half within three years, and the proportion of academic assets licensed before any human data falls, indicating that institutions retain assets longer and on better terms.","rationale":"Institutions respond to liability exposure: after high-profile gene therapy adverse events, academic sponsorship of first-in-human trials fell sharply where insurance costs rose. Pooling risk across many trials is standard for rare, high-severity events, and the actual claims record of early-phase oncology trials is small relative to premiums charged.","test":"Establish the pool in one country for three years, track academic first-in-human sponsorships, premiums paid and claims, and compare with a neighbouring country without the scheme.","maturity":"speculative","actor":"policy","cost":"medium","horizonYears":2},"route":"/ideas/idea-fund-academic-sponsor-indemnity-pool/","neighbours":{"idea":[{"id":"idea-fund-global-academic-phase-one-network","kind":"idea","name":"A global first-in-human network for academic cancer trials with single ethics review","route":"/ideas/idea-fund-global-academic-phase-one-network/"},{"id":"idea-fund-public-nonprofit-cro","kind":"idea","name":"A national non-profit contract research organisation for academic oncology trials","route":"/ideas/idea-fund-public-nonprofit-cro/"},{"id":"idea-fund-hospital-exemption-registry","kind":"idea","name":"Hospital-exemption cell therapies at scale, backed by a shared registry","route":"/ideas/idea-fund-hospital-exemption-registry/"}],"bottleneck":[{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"}],"paper":[{"id":"paper-butler-nature","kind":"paper","name":"Translational research: crossing the valley of death","route":"/key-papers/paper-butler-nature/"}]}}